SG-BCC 2021 - 17th St.Gallen International Breast Cancer Conference (Virtual Meeting)
Mar 17 - Mar 21, 2021 | ViennaAustria
LARVOL is not affiliated with 17th St.Gallen International Breast Cancer Conference (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 12 abstracts linked to Trials
[VIRTUAL] Patients’ quality of life and side effect perceptions in monarchE, a study of abemaciclib plus endocrine therapy in adjuvant treatment of HR+, HER2-, node-positive, high- risk, early breast cancer
[VIRTUAL] 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial
[VIRTUAL] Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer
[VIRTUAL] Bringing diarrhea under CONTROL: dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer
[VIRTUAL] Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial
[VIRTUAL] Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer
[VIRTUAL] Axillary surgery in node-positive breast cancer
[VIRTUAL] One size fits all? Novel pulse biopsy platform offers improved needle control, high tissue yield and multiple needle options – pre-clinical results
[VIRTUAL] 5-yr DMFS outcomes on the pre-operative use of MammaPrint and BluePrint for neoadjuvant decisions in the NBREaST II trial
[VIRTUAL] MammaPrint, BluePrint, and full-genome data linked with clinical data to evaluate new gene EXpression profiles (FLEX): a real-world dataset and investigator-initiated protocols in ESBC
[VIRTUAL] Comparing the temporal changes of cosmetic, QoL and patient satisfaction achieved with breast reconstruction and contralateral symmetrisation techniques. (ClinicalTrials.gov: NCT04356235)
[VIRTUAL] Residual disease after a neoadjuvant therapy: a strong prognostic and potentially predictive biomarker to personalize therapy